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Medulloblastoma, a primitive neuroecto-
dermal tumor of the posterior fossa, is
the most common central nervous sys-
tem (CNS) malignancy of childhood.
Despite aggressive multimodal therapy
with surgery, radiation, and chemothera-
py, 5-year survival rates have only
recently approached >60% (Packer et
al., 1999). In this preview we will address
the genetic underpinnings of medul-
loblastoma and the role that Sonic
hedgehog (Shh) signaling plays in this
disease. Recent work by Taylor et al.
(2002) extends our understanding of
medulloblastoma oncogenesis and its
relationship to normal developmental
programs.
Medulloblastomas are thought to
derive from immature granule cells of the
cerebellum and comprise several histo-
logical and prognostic subgroups. The
desmoplastic subtype is distinguished
from “classic” medulloblastoma by the
presence of relatively acellular nodules
within the otherwise densely cellular sea
of malignant cells. Expression of particu-
lar markers, such as TrkC, in tumor cells,
has been shown to predict a relatively
favorable outcome (Louis et al., 2002). A
significant advance in our understanding
of medulloblastoma tumorigenesis was
the recognition that mutations of the Shh
receptor, Patched (PTCH), were strongly
associated with desmoplastic medul-
loblastoma. Germline PTCH mutations
are etiologic in Gorlin’s syndrome (also
called Nevoid Basal Cell Carcinoma
Syndrome), which is characterized by
developmental anomalies and high rates
of both basal cell carcinoma and medul-
loblastoma. Moreover, about 10%–20% of
sporadic tumors, typically the desmoplas-
tic variant, contain mutations within the
Shh-PTCH pathway (Louis et al., 2002).
Shh signaling is essential for the
development of the mammalian CNS and
is the major mitogenic pathway regulating
proliferation of immature granule cells of
the cerebellum (Wechsler-Reya and
Scott, 2001). hedgehog was originally
identified as a “segment polarity” gene by
Figure 1. Mutations in Hedge-
hog (Hh) signaling predispose
to tumorigenesis
Mutant alleles of PTCH and
SMOH that result in activation
of Hedgehog signaling are
etiologic in basal cell carci-
noma and medulloblastoma.
Whether SMOH signaling di-
rectly regulates GLI activity is
unclear. Recent work impli-
cates SUFU as a functional
repressor of GLI proteins that
are thought to mediate acti-
vation of Hh transcriptional
targets (Taylor et al., 2002).
SUFU proteins in the nucleus
repress GLI transcriptional ac-
tivity by recruiting SAP18, a
component of the mSin3 and
histone deacetylase com-
plex (Cheng and Bishop,
2002). Furthermore, SUFU ex-
ports GLI from the nucleus
and the cytoplasm, where is
targeted for degradation.
Together, mutations in PTCH, SMOH, and SUFU (indicated by asterisks) account for the major-
ity of cases of human desmoplastic medulloblastoma. Note that the cartoon represents a
simplified scheme for vertebrate Hh signaling with particular emphasis on oncogenic muta-
tions. For detailed summary of invertebrate Hh signaling, see Ingham and McMahon (2001).
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Medulloblastoma: A problem of developmental biology
The identification of SUFU mutations in desmoplastic medulloblastoma provides new insights into vertebrate Hedgehog
signaling and brain tumor formation.
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Nusslien-Volhard and Wieschaus in a
mutational screen of Drosophila em-
bryos, and its vertebrate orthologs take
their names from hedgehog species,
both real and virtual (Ingham and
McMahon, 2001). Hedgehog proteins
bind to the multipass receptor PTCH,
which functions as a repressor of the
pathway. Shh binding to PTCH is thought
to relieve inhibition of Smoothened
(SMOH), a seven-span transmembrane
protein with homology to G protein-cou-
pled receptors (Figure 1). This results in
upregulation of Shh transcriptional tar-
gets, including PTCH itself as well as
members of the vertebrate GLI family of
zinc-finger transcription factors. GLI pro-
teins are then thought to mediate the
transcriptional program of Hedgehog sig-
naling (Ingham and McMahon, 2001;
Ruiz-i-Altabla et al., 2002).
SUFU, encoding the human ortholog
of Drosophila suppressor of fused,
appears to have a conserved role in the
repression of Hedgehog signaling.
However, genetic and biochemical stud-
ies suggest that its mode of action is dis-
tinct from that of PTCH. SUFU exerts its
repressor role by physically interacting
with GLI proteins in both the cytoplasm
and the nucleus (Ingham and McMahon,
2001). In the cytoplasm, SUFU can
sequester GLI proteins, rendering them
susceptible to degradation, while in the
nucleus SUFU appears to recruit SAP18,
a component of the mSin3 and histone
deacetylase complex, to form a repressor
unit that inhibits GLI transcriptional activi-
ty (Cheng and Bishop, 2002). Finally,
SUFU promotes the active export of GLI
proteins from the nucleus via a CRM-1-
dependent mechanism (Figure 1).
Although mutations in PTCH have
been found in medulloblastoma and its
oncogenic properties have been validated
in animal models, these lesions only
account for a minority of cases (?10%;
Wechsler-Reya and Scott, 2001). The
phenotype of the index case studied by
Taylor and coworkers (2002) was sugges-
tive of Gorlin’s syndrome; however, the
patient was found to have intact PTCH
loci. This prompted them to investigate
mutations in other Shh pathway elements.
Several chromosomal abnormalities are
commonly associated with medulloblas-
toma including loss of chromosome 10q
in 41% of cases. Interestingly, SUFU
localized to chromosome 10q24.3 and,
indeed, Taylor et al. (2002) confirmed
mutation of SUFU in the index case. They
went on to identify three further indepen-
dent SUFU mutations in a series of 46
medulloblastomas. The SUFU mutations
were associated with the desmoplastic
subtype of medulloblastoma, and loss of
heterozygosity was found in each case.
Because most of these mutations predict-
ed truncated SUFU proteins, the authors
tested mutant forms for activity in vitro.
This revealed that mutant SUFU proteins
were unable to bind to GLI1 or GLI2 or to
promote the export of GLI from the nucle-
us. Additionally, mutant SUFU was unable
to suppress GLI-dependent transcription.
Together, these data link the loss of SUFU
function to the formation of desmoplastic
medulloblastoma and provide the first
demonstration of functional requirements
for SUFU in vertebrate organisms. The
work is significant in a further respect.
Although mutations of PTCH and SMOH
are thought to result in activation of Hh
targets, it has not been clear whether GLI
or other Hh targets are responsible for the
oncogenic effects. The findings of Taylor
et al. (2002) implicate GLI activity per se
in the genesis of human medulloblas-
tomas.
It thus appears that mutations in the
Shh pathway will account for most
cases of desmoplastic medulloblas-
toma (Pomeroy et al., 2002). Recent
clinical success with tyrosine kinase
and farnesyltransferase inhibitors has
focused attention on generation of
chemotherapeutic agents based on a
thorough understanding of tumor bio-
logy. Indeed, jervine and cyclopamine,
two plant-derived alkaloids first des-
cribed for their etiologic role in endemic
holoprosencephaly in livestock, are
potent and relatively specific inhibitors
of Hedgehog signaling and could prove
a useful class of agents to employ in
certain cases of desmoplastic medul-
loblastoma (Figure 1).
In the monograph Cancer: A Problem
of Developmental Biology, G. Barry
Pierce and colleagues predicted that a
precise understanding of the develop-
mental milieu would yield important
insights into mechanisms that control
cancer (Pierce et al., 1978). Functional
studies of PTCH tumor suppressor func-
tion coupled with the findings of Taylor et
al. (2002) comprise clear examples of
how similar mechanisms can underlie
both CNS development and formation of
medulloblastoma. Such interdisciplinary
crossfertilization is likely to yield further
insight into brain tumorigenesis and aid in
the generation of tumor-specific therapeu-
tic strategies.
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